



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 47/48		A2	(11) International Publication Number: WO 00/45849																														
			(43) International Publication Date: 10 August 2000 (10.08.00)																														
(21) International Application Number: PCT/US00/02943		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).																															
(22) International Filing Date: 4 February 2000 (04.02.00)																																	
(30) Priority Data: 60/118,802 5 February 1999 (05.02.99) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>																															
(71) Applicants (for all designated States except US): GENZYME CORPORATION [US/US]; One Mountain Road, Framingham, MA 01701-9322 (US). STRESSGEN BIOTECHNOLOGIES CORPORATION [CA/CA]; 350-4243 Glanford Avenue, Victoria, British Columbia V8Z 4B9 (CA).																																	
(72) Inventors; and																																	
(75) Inventors/Applicants (for US only): SCHEULE, Ronald, K. [US/US]; 26 East Street, Hopkinton, MA 01748 (US). YEW, Nelson, S. [US/US]; 25 Rockdale Hill Circle, West Upton, MA 01568 (US). MIZZEN, Lee [CA/CA]; 1936 Quamichan Street, Victoria, British Columbia V8S 2C4 (CA). KADHIM, Salam, Abdul [CA/CA]; Unit 66, 14 Erskine Lane, Victoria, British Columbia V8Z 7J7 (CA).																																	
(74) Agents: GARRETT, Arthur, S.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street N.W., Washington, DC 20005-3315 (US) et al.																																	
(54) Title: USE OF CATIONIC LIPIDS TO GENERATE ANTI-TUMOR IMMUNITY																																	
(57) Abstract																																	
<p>A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides for methods of generating an immunostimulatory response against the tumor cell present during treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.</p>																																	
<table border="1"> <caption>Data extracted from the bar charts</caption> <thead> <tr> <th>Cytokine</th> <th>pCF1-CAT</th> <th>(m) pCF1-CAT</th> <th>pCFA-299-CAT</th> <th>pCFA-299-10M-CAT</th> <th>NAIVE</th> </tr> </thead> <tbody> <tr> <td>TNF-α (pg/ml)</td> <td>~450</td> <td>~750</td> <td>~650</td> <td>~10</td> <td>~10</td> </tr> <tr> <td>IFN-γ (pg/ml)</td> <td>~950</td> <td>~450</td> <td>~600</td> <td>~10</td> <td>~10</td> </tr> <tr> <td>IL-6 (pg/ml)</td> <td>~550</td> <td>~200</td> <td>~550</td> <td>~50</td> <td>~10</td> </tr> <tr> <td>IL-12 (pg/ml)</td> <td>~2500</td> <td>~800</td> <td>~2800</td> <td>~2500</td> <td>~10</td> </tr> </tbody> </table>				Cytokine	pCF1-CAT	(m) pCF1-CAT	pCFA-299-CAT	pCFA-299-10M-CAT	NAIVE	TNF- α (pg/ml)	~450	~750	~650	~10	~10	IFN- γ (pg/ml)	~950	~450	~600	~10	~10	IL-6 (pg/ml)	~550	~200	~550	~50	~10	IL-12 (pg/ml)	~2500	~800	~2800	~2500	~10
Cytokine	pCF1-CAT	(m) pCF1-CAT	pCFA-299-CAT	pCFA-299-10M-CAT	NAIVE																												
TNF- α (pg/ml)	~450	~750	~650	~10	~10																												
IFN- γ (pg/ml)	~950	~450	~600	~10	~10																												
IL-6 (pg/ml)	~550	~200	~550	~50	~10																												
IL-12 (pg/ml)	~2500	~800	~2800	~2500	~10																												